Company Description
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets.
The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health.
The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025.
The company was founded in 2019 and is based in Naples, Florida.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | James Bligh |
Contact Details
Address: 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103 United States | |
| Phone | 646 491 9132 |
| Website | cdtequity.com |
Stock Details
| Ticker Symbol | CDT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1896212 |
| CUSIP Number | 20678X700 |
| ISIN Number | US20678X7003 |
| Employer ID | 87-3272543 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James Bligh | Co-Founder, Chief Executive Officer and Director |
| Dr. Joanne M. Holland | Chief Scientific Officer |
| Dr. David Joszef Tapolczay | Head of Strategy and Licensing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 13, 2026 | 424B3 | Prospectus |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 8, 2026 | SCHEDULE 13G/A | Filing |
| Oct 7, 2026 | SCHEDULE 13G | Filing |
| Oct 7, 2026 | SCHEDULE 13G/A | Filing |
| Oct 7, 2026 | SCHEDULE 13G/A | Filing |
| Oct 2, 2026 | 424B3 | Prospectus |
| Sep 25, 2026 | 8-K | Current Report |
| Sep 18, 2026 | 424B3 | Prospectus |